We are live on ! Find out more
AMBI

Ambit Biosciences Corp
AMBI

Delisted

AMBI was delisted on the 10th of November, 2014.

Back to rankings

46 hedge funds and large institutions have $78.8M invested in Ambit Biosciences Corp in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

31% more funds holding

Funds holding: 35 → 46 (+11)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $79.3M → $78.8M (-$510K)

Holders
46
Holders Change
+11
Holders Change %
+31.43%
% of All Funds
1.33%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
15
Increased
14
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.47M
2
CA
Commerzbank Aktiengesellschaft
Germany
+$753K
3
Macquarie Group
Macquarie Group
Australia
+$651K
4
EAM
Eventide Asset Management
Massachusetts
+$605K
5
IG
ING Group
Netherlands
+$531K

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$1.89M
2
SFM
Sphera Funds Management
Israel
-$908K
3
SM
Sabby Management
Florida
-$627K
4
HCM
Highbridge Capital Management
New York
-$268K
5
GPP
Great Point Partners
Connecticut
-$142K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFA
26
BlackRock Fund Advisors
California
$240K +$93.9K +8,849 +51%
RIL
27
Rothschild Investment LLC
Illinois
$240K +$279K +26,330 New
SFM
28
Soros Fund Management
New York
$231K +$268K +25,300 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$217K +$22.6K +2,130 +10%
Northern Trust
30
Northern Trust
Illinois
$180K +$16.7K +1,571 +9%
CS
31
Credit Suisse
Switzerland
$178K +$207K +19,469 New
SIM
32
Spark Investment Management
New York
$177K -$37.1K -3,500 -15%
Two Sigma Investments
33
Two Sigma Investments
New York
$156K +$181K +17,100 New
Nomura Holdings
34
Nomura Holdings
Japan
$132K +$151K +14,204 New
Wells Fargo
35
Wells Fargo
California
$118K +$137K +12,901 New
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$103K +$120K +11,344 New
N
37
Natixis
France
$91K +$106K +10,000 New
PCM
38
Prelude Capital Management
New York
$34K +$39.3K +3,700 New
BJ
39
BlackRock Japan
Japan
$16K +$15.5K +1,459 +468%
Barclays
40
Barclays
United Kingdom
$12K -$29.3K -2,757 -68%
Citigroup
41
Citigroup
New York
$5K -$4.68K -441 -44%
AllianceBernstein
42
AllianceBernstein
Tennessee
$4K +$2.99K +282 +196%
MTIP
43
Magee Thomson Investment Partners
California
$3K – – –
TRCT
44
Tower Research Capital (TRC)
New York
$2K -$14.6K -1,376 -86%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2 +$1.89K +178 New
SM
46
Sabby Management
Florida
– -$627K -65,000 Closed
HCM
47
Highbridge Capital Management
New York
– -$268K -27,738 Closed
Bank of America
48
Bank of America
North Carolina
– -$1K -63 Closed
1
2

AMBI Hedge Fund Activity: Q1 2014 in Review

46 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q1 2014, worth a combined $78.8M — down 0.64% from $79.3M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new AMBI positions and 4 closed out — a net gain of 11 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.47M. The largest seller was Redmile Group, cutting an estimated $1.89M.

  • 46 institutional investors held Ambit Biosciences Corp (AMBI) as of Q1 2014, up from 35 in Q4 2013.
  • Funds reported $78.8M of Ambit Biosciences Corp stock for Q1 2014, down 0.64% quarter-over-quarter.
  • 15 funds opened new Ambit Biosciences Corp positions in Q1 2014 and 4 closed out, a net change of +11 holders.
  • The largest Ambit Biosciences Corp buyer in Q1 2014 was Vanguard Group, an estimated $1.47M added.
  • The largest Ambit Biosciences Corp seller in Q1 2014 was Redmile Group, an estimated $1.89M sold.

Based on aggregated 13F filings for Q1 2014.